Abeona Therapeutics (ABEO)
(Delayed Data from NSDQ)
$5.57 USD
+0.11 (2.01%)
Updated Sep 4, 2024 04:00 PM ET
After-Market: $5.58 +0.01 (0.18%) 7:36 PM ET
NA Value
NA Growth NA Momentum NA VGMBrokerage Reports
0 items in cart
Abeona Therapeutics Inc. [ABEO]
Reports for Purchase
Showing records 81 - 89 ( 89 total )
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Patient Dosing Initiated; 1Q 2016 Financials Reported; Reiterate Buy
Provider: Rodman & Renshaw, Co.
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage; Reiterating Buy and Instituting $17 Price Target
Provider: H.C. Wainwright & Co., Inc.
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Transferring Coverage; Reiterating Buy and Instituting $17 Price Target
Provider: Rodman & Renshaw, Co.
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MORNING SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
MID-DAY SUMMARY
Provider: Roth Capital Partners, Inc.
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Licensed Vector for Fanconi Anemia Gene Therapy
Provider: Roth Capital Partners, Inc.
Analyst: PIROS E
Company: Abeona Therapeutics Inc.
Industry: Medical - Biomedical and Genetics
Orphan Gene Therapy Program to Enter Clinic by Year End; Reit Buy Rating and $15 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A